Skip to content

the Efficacy and Safety of Spirulina Maxima Extract on Improvement of Cognitive Function

A 12 Weeks, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Spirulina Maxima Extract on Improvement of Cognitive Function

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04431843
Enrollment
80
Registered
2020-06-16
Start date
2020-03-17
Completion date
2020-11-26
Last updated
2023-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Function

Keywords

Spirulina maxima Extract, Cognitive Function

Brief summary

This study was the evaluate the efficacy and safety of Spirulina maxima extract on the improvement of Cognitive Function

Detailed description

This study was 12 weeks, randomized, double-blind, placebo-controlled human trial to evaluate. 80 subjects participated in Spirulina maxima extract or placebo group. To evaluate the changes in the evaluation items when Spirulina maxima extract was taken 12 weeks compared with placebo.

Interventions

DIETARY_SUPPLEMENTSpirulina maxima extract

once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 1.5 g/day) for 12 week

DIETARY_SUPPLEMENTPlacebo

once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 0 g/day) for 12 week

Sponsors

Chonbuk National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Persons who are at least 60 years of age at screening * Persons who have Korean Mini-Mental Status Examination(K-MMSE) result in 25-28 points * Persons who agree to voluntary participation and to comply with the Notice after fully hearing and understanding the details of this human trial

Exclusion criteria

* Patients with a past history of treatment with Axis I disorder in SCID(Structured Clinical Interview for DSM-IV) which is a structured clinical interview in the Diagnostic and Statistical Manual of Mental Disorders at Screening or who have been treated within the last 3 years * Patients with BMI(Body Mass Index)\<18.5 kg/m\^ or 35 kg/m\^≤BMI(Body Mass Index) * Patients with alcohol abuse or dependence within the last 3 months * Patients who have clinically significant following severe illness (i.e., Cardiovascular, endocrine system, immune system, respiratory system, hepatobiliary system, kidney and urinary system, neuropsychiatric, musculoskeletal, inflammatory, blood and tumors, gastrointestinal diseases, etc.) * Patients with a history of clinically significant hypersensitivity to Spirulina Maxima * Patients taking medicines, health functional foods or herbal medicines related to the improvement of cognitive function and memory within 1 month before screening * Patients who ingested Spirulina Maxima extract's health functional food within 1 month before screening * Patients who whole blood donation within 1 months before the first ingestion or Component blood donation within 2 weeks * Patients who participate in another human trial within 3 months * Those who show the following results in the Laboratory test * AST, ALT \> 3 times upper limit of the normal range * Other significant laboratory test opinion * Patients who are deemed unsuitable for participating in the human trial due to other reasons

Design outcomes

Primary

MeasureTime frameDescription
Changes of Visual learning test12 weeksVisual learning test of CNT(Computerized neurocognitive function test) was measured in baseline and 12 week. And changes of result from the test were utilized.
Changes of Visual working memory test12 weeksVisual working memory test of WMT(working memory tasks) was measured in baseline and 12 week. And changes of result from the test were utilized.
Changes of Verbal learning test12 weeksVerbal learning test of CNT(Computerized neurocognitive function test) was measured in baseline and 12 week. And changes of result from the test were utilized.

Secondary

MeasureTime frameDescription
MoCA-K; Korean Version of the Montreal Cognitive Assessment12 weeksThe cognitive function evaluation using the Montreal Cognitive Assessment(MoCA-K) is a total of 8 items, and evaluates cognitive functions such as time / execution power, vocabulary, memory, attention, sentence, abstraction, delayed recall, and orientation. Time / execution power's total score is 5 points, vocabulary's total score is 3 points, attention's total score is 3 points, sentence's total score is 3 points, abstraction's total score is 2 points, delayed recall's total score is 5 points, orientation's total score is 6 points. It takes about 10 minutes to complete, and the total score is 30 points and total score make sum score. A score of 23 points or more is regarded as normal. If you have less than 6 years of education, add 1 point. It takes about 10 minutes to complete, and the score is 30 points. A score of 23 points or more is regarded as normal. If you have less than 6 years of education, add 1 point.
Changes of TAS(Total antioxidant status)12 weeksTotal antioxidant status(TAS) was measured in baseline and 12 week. And changes of result from the test were utilized.
Changes of Auditory continuous performance test12 weeksAuditory continuous performance test of CNT(Computerized neurocognitive function test) was measured in baseline and 12 week. And changes of result from the test were utilized.
BDNF; Brain-derived neurotrophic factor12 weeksBrain-derived neurotrophic factor(BDNF)(pg/mL) was measured in baseline and 12 week.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026